Q-omics provides the consensus-scored DNM1 profile across patient tissues and cancer cell-line models. DNM1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DNM1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DNM1 protein abundance shows 34,476 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where DNM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM1 survival associations across molecular data types. DNM1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM1 RNA expression–survival associations across cancer types. High DNM1 expression shows unfavorable associations in ACC, BLCA, COAD, LIHC, THCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DNM1 RNA expression.
This table summarizes DNM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DNM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM1 shows higher tumor expression in HNSC, KIRP, LUAD, COAD, KIRC and LUSC. The HNSC box plot shows higher DNM1 RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with DNM1 in patient tissues and cancer cell lines. In patient samples, DNM1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
